This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

US states say Sun, Taro generic drug settlements shouldn't limit recovery for citizens

( December 2, 2025, 23:31 GMT | Official Statement) -- MLex Summary: US state plaintiffs filed a brief in court arguing that they should not be bound by end-payers’ settlement with Sun and Taro in a case over the price-fixing of generic pharmaceuticals, arguing that the private class do not adequately represent the broader interests of each state in law enforcement and fair dealing in the marketplace. They said that state government should not be bound by private litigation when the state government’s action seeks to enforce a state statute that implicates both public and private interests.See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections